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A B S T R A C T
The purpose of this report is to analyze long-term clinical outcomes of patients exposed to plerixafor plus
granulocyte colony-stimulating factor (G-CSF) for stem cell mobilization. This was a study of patients with
non-Hodgkin lymphoma (NHL; n = 167) and multiple myeloma (MM; n = 163) who were enrolled in the longterm follow-up of 2 pivotal phase III studies (NCT00741325 and NCT00741780) of 240 μg/kg plerixafor plus
10 μg/kg G-CSF, or placebo plus 10 μg/kg G-CSF to mobilize and collect CD34+ cells for autologous hematopoietic stem cell transplantation. Overall survival (OS) and progression-free survival (PFS) were evaluated over
a 5-year period following the ﬁrst dose of plerixafor or placebo. The probability of OS was not signiﬁcantly
different in patients with NHL or MM treated with plerixafor or placebo (NHL: 64%; 95% conﬁdence interval
[CI], 56% to 71% versus 56%; 95% CI, 44% to 67%, respectively; MM: 64%; 95% CI, 54% to 72% versus 64%; 95%
CI, 53% to 73%, respectively). In addition, there was no statistically signiﬁcant difference in the probability of
PFS over 5 years between treatment groups in patients with NHL (50%; 95% CI, 44% to 67% for plerixafor versus
43%; 95% CI, 31% to 54% for placebo) or those with MM (17%; 95% CI, 10% to 24% for plerixafor versus 30%;
95% CI, 21% to 40% for placebo). In this long-term follow-up study, the addition of plerixafor to G-CSF for stem
cell mobilization did not affect 5-year survival in patients with NHL or patients with MM.
© 2018 American Society for Blood and Marrow Transplantation. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

INTRODUCTION
High-dose chemotherapy combined with autologous hematopoietic stem cell transplantation (auto-HSCT) is the
standard of care for patients with relapsed or chemosensitive non-Hodgkin lymphoma (NHL) and multiple myeloma

Financial disclosure: See Acknowledgments on page 1193.
* Correspondence and reprint requests: John F. DiPersio, MD, PhD, Division
of Oncology, Washington University Medical School, 660 South Euclid Avenue,
St. Louis, MO 63110.
E-mail address: jdipersi@wustl.edu (J.F. DiPersio).
†
Employees of Sanoﬁ at the time of the study.

(MM) [1-3]. Auto-HSCT improves hematologic recovery in patients by reconstituting hematopoiesis following high-dose
chemotherapy [3]. In patients with relapsed or chemosensitive NHL, high-dose chemotherapy with auto-HSCT has been
shown to increase disease-free survival [4], whereas in MM,
a combination of high-dose chemotherapy with auto-HSCT
improves progression-free survival (PFS) and overall survival (OS) [5,6]. The minimum number of cells generally
acceptable for transplantation is ≥2 × 106 CD34+ cells/kg [7].
Transplanting fewer than this number of cells may result in
delayed engraftment of both platelets and neutrophils [8]. The
target number of cells for a single transplant was deﬁned by

https://doi.org/10.1016/j.bbmt.2018.01.039
1083-8791/© 2018 American Society for Blood and Marrow Transplantation. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Weaver et al. [9] as ≥5 × 106 CD34+ cells/kg, which is important for short-term outcomes, resulting in earlier and more
consistent neutrophil and especially platelet engraftment compared with transplants with lower cell doses [10]. In some
studies, transplant doses of ≥5 × 106 CD34+ cells/kg have been
associated with longer disease-free survival and OS compared with lower transplant doses [11-13]. One recent
retrospective analysis comparing patients with NHL mobilized with chemotherapy plus granulocyte colony-stimulating
factor (G-CSF) (median, 12.0 × 106 CD34+ cells/kg) versus G-CSF
alone (median, 5.0 × 106 CD34+ cells/kg) found no difference between the groups in either event-free survival or OS
[14]. It should be noted that for patients with MM, subsequent or tandem auto-HSCT can be considered as well [15].
Obtaining a suﬃcient quantity of cells for auto-HSCT is
diﬃcult in approximately 20% to 25% of patients [3,16-18].
These include patients with NHL, elderly patients [19], heavily
pretreated patients [20-22], and patients with MM who previously received multiple cycles of lenalidomide or underwent
auto-HSCT [23].
Employing, an effective stem cell mobilization regimen
plays a critical role in optimizing engraftment and outcomes in patients with NHL and MM. Until recently, there
were 2 main approaches to stem cell mobilization that involved the use of growth factors, such as G-CSF alone, or in
conjunction with chemotherapy [24]. The administration of
chemotherapy before the use of G-CSF produces a higher yield
of stem cells for autologous transplantation, but this is not
effective for all patients [24].
Plerixafor, a CXCR4 receptor antagonist, is used in combination with G-CSF to mobilize hematopoietic stem cells into
the peripheral blood (PB) for collection and subsequent autoHSCT in patients with lymphoma or MM [25,26]. Plerixafor
selectively and reversibly antagonizes the CXCR4 chemokine
receptor and blocks binding of stromal cell-derived factor1α (SDF-1α) [27]. The interruption of the CXCR4/SDF-1α
interaction provides a mechanism for mobilization of CD34+
stem cells from the bone marrow to the PB, where they can
be collected for auto-HSCT. Plerixafor provides another option
for transplantation, and G-CSF plus plerixafor augments the
mobilization of CD34+ cells, particularly in patients who are
considered poor mobilizers [28-30]. The stem cells mobilized in apheresis products by the combination of G-CSF plus
plerixafor have been shown to differ from those mobilized
by G-CSF alone, with a higher proportion of cells in the growth
phase, higher numbers of B and T lymphocytes, natural killer
cells, dendritic cells, and primitive CD34+ cells [24,31-35].
Two pivotal multicenter, randomized, double-blind,
placebo-controlled phase III studies have evaluated the efﬁcacy and safety of plerixafor plus G-CSF versus placebo plus
G-CSF in mobilizing and collecting hematopoietic stem cells.
[36,37]. These trials demonstrated that plerixafor plus G-CSF
can generate optimal numbers of cells for auto-HSCT in patients with NHL or MM.
Findings from the NHL study (Study 3101; NCT00103610)
showed that compared with placebo plus G-CSF, plerixafor
plus G-CSF signiﬁcantly increased the percentage of patients in whom the target stem cell collection (≥5 × 106 CD34+
cells/kg) was achieved within 4 apheresis days (20% versus
59%) [36].
Findings from the MM study (Study 3102; NCT00103662)
also showed that plerixafor plus G-CSF signiﬁcantly increased the percentage of patients in whom the target stem
cell collection (≥6 × 106 CD34+ cells/kg to facilitate tandem
transplantation) was achieved within 2 apheresis days,

compared with placebo plus G-CSF (72% versus 34%) [37]. In
both studies, auto-HSCT after mobilization with plerixafor and
placebo resulted in successful engraftment of neutrophils and
platelets. Durability of grafts was similar for plerixafor and
placebo through 12 months of follow-up, and both regimens were associated with similar survival rates at 12 months
post-transplantation [36,37]. To date, there is no evidence of
differences in the time to successful neutrophil or platelet engraftment, in adverse events during stem cell mobilization,
or in mortality at 12 months between patients receiving G-CSF
plus plerixafor compared with those receiving G-CSF alone
[18,38,39].
To examine clinical outcomes beyond 1 year, we undertook a long-term, observational study of patients with NHL
or MM enrolled in each of the phase III pivotal studies. We
assessed OS and PFS over a 5-year period following the ﬁrst
dose of study drug (ie, plerixafor or placebo) administered
in Studies 3101 and 3102. Furthermore, because the use of
autologous PB stem cells for transplantation could be associated with the risk of contamination of the graft with tumor
cells [40], the assessment of OS and PFS may serve as a surrogate for determining the risk of plerixafor mobilizing
malignant cells from the bone marrow during hematopoietic stem cell mobilization. Very limited data from small
numbers of patients indicate that tumor cell traﬃcking to the
peripheral blood is not signiﬁcantly increased after mobilization with G-CSF plus plerixafor compared with G-CSF alone
in patients with MM or NHL [41,42]. It also should be noted
that the clinical signiﬁcance of tumor cell mobilization of
myeloma tumor cell contamination of mobilized apheresis
products on long-term outcomes is unclear.
METHODS
Study Design
This study was a long-term, observational follow-up (hereafter referred to as the “LTF study”) to the 2 phase III multicenter, randomized,
double-blind, placebo-controlled, comparative trials of plerixafor plus G-CSF
(hereafter referred to as “plerixafor”) versus placebo plus G-CSF (hereafter
referred to as “placebo”) to mobilize and collect CD34+ cells for auto-HSCT
in patients with NHL (Study 3101) [36] and patients with MM (Study 3102)
[37]. Patients were eligible if they had previously received at least 1 dose
of study treatment (placebo or plerixafor) in either study and had a signed
informed consent for follow-up data collection. Patients who failed to mobilize or who did not achieve at least 2 × 106 CD34+ cells/kg within ≤4 days
of apheresis after treatment with either placebo or plerixafor were allowed
to enter a “rescue” procedure. Those patients received open-label plerixafor
with the aim of collecting a transplantable dose of CD34+ cells, and were
assigned to the plerixafor treatment group for analysis.
In both studies, data were collected for OS evaluation at 100 days, 6
months, and 12 months after auto-HSCT. The initial objective of the LTF study
was to assess OS over a 5-year period following administration of the ﬁrst
dose of plerixafor or placebo in Studies 3101 and 3102, and was later expanded to include PFS.
These studies were registered at www.ClinicalTrials.gov (NCT00741325
for 3101-LTF and NCT00741780 for 3102-LTF) and conducted in accordance with International Conference on Harmonisation Good Clinical Practice,
the principles speciﬁed in the Declaration of Helsinki and its amendments, and all applicable national and international laws. All patients who
had consented and received at least 1 dose of plerixafor or placebo in Studies
3101 and 3102 were eligible for inclusion in the LTF study. After consenting to long-term data collection, patients were free to withdraw consent or
discontinue participation at any time at the discretion of the investigator
or sponsor. There were no formal exclusion criteria.
Endpoints
The primary endpoint analysis was OS and PFS. This analysis included
all patients enrolled in Studies 3101 and 3102, as well as patients enrolled
in the LTF studies. Data for survival and disease state were collected up to
5 years after the ﬁrst study drug administration in Studies 3101 and 3102.
Data from patients who did not enroll for the LTF study was included up to
either their last reported follow-up date during the original 3101 and 3012
study periods, or until the date of their LTF study registration form.
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OS was deﬁned as the time from the date of ﬁrst study drug exposure
(placebo or plerixafor) until the date of death due to any cause. PFS was
deﬁned as the time from the date of ﬁrst study drug exposure until the date
of reported disease progression, disease relapse, or death due to any cause,
whichever occurred ﬁrst. If a disease progression/relapse or death event occurred but the date of the event was missing, the date of follow-up contact
at which the event was reported was used as the best approximation.
PFS was determined using the Revised Response Criteria for Malignant
Lymphoma [43] and the International Uniform Response Criteria for Multiple Myeloma [44]. Time points and testing requirements were not speciﬁed
for assessment of PFS, and data were not collected in the case report form
to document the determination of PFS.
Long-Term Follow-Up Schedule
The LTF schedule was determined by whether or not the patient underwent auto-HSCT during Study 3101 or 3102. For patients who underwent
auto-HSCT (including those who withdrew or were lost to follow-up), followup began at 18 months post auto-HSCT or at LTF study entry (ie, signed
informed consent) and occurred every 6 months (±3 months) for 5 years
after the ﬁrst dose of study treatment. For patients who did not undergo
auto-HSCT in Study 3101 or 3102, follow-up occurred every 6 months (±3
months) for a total follow-up period of 5 years following the ﬁrst dose of
study treatment (placebo or plerixafor).
Data Collection
For this observational study, data for disease progression/relapse and
death were collected from the original data for Studies 3101 and 3102, LTF
study registration forms, and the LTF study itself. Data from patients who
did not enroll in the LTF study were limited to that collected during Study
3101 or 3102 and/or the LTF study registration form.
Assessments
The principal population assessed for eﬃcacy was the primary intentto-treat (ITT) population, which comprised all randomized patients. Data
analyzed for the ITT population were based on the actual randomization assignment. The Per Protocol population consisted of all ITT patients who
received any fraction of study treatment (plerixafor or placebo), completed the apheresis period, and did not have any major protocol deviations
that signiﬁcantly impacted the assessment of eﬃcacy, and included all patients who had received at least 1 dose of study drug or placebo, as well as
those patients who failed stem cell collection on the study and had elected
to enter the “rescue protocol”.
Death and disease progression/relapse status were captured at study entry
and at each follow-up contact, which occurred every 6 months until 5 years
from the date of ﬁrst dose. In addition, the investigators and treating physicians were encouraged to record any additional treatments (eg,
transplantation, chemotherapy, or radiotherapy) received since the last study
contact.
Not all sites provided information on the nature of additional therapy
and the reason for its administration. Patients could have received
maintenance/adjuvant therapy either in another study or as a result of study
site clinical practice, and it was necessary to evaluate the effect of presumed maintenance/adjuvant treatment on disease progression rate.
Consequently, a post hoc analysis was performed using a “composite (triple)
endpoint” event, deﬁned by death (yes or no), progression/relapse (yes or
no), or introduction of any additional treatments for the management of MM,
whichever occurred ﬁrst.
Statistical Analysis
OS, PFS and the composite triple endpoint were estimated using the
Kaplan-Meier (KM) method. The 25th, 50th (median), and 75th OS and PFS
percentiles (along with 95% conﬁdence intervals [CIs] for these quartiles, if
estimable) were determined. The OS and PFS probabilities along with 95%
CIs at 12, 24, 36, 48, and 60 months were estimated from the KM method.
The log-rank test and the Wilcoxon test (Breslow procedure) were used to
compare treatment groups (plerixafor versus placebo). The statistical analysis system was used to perform all analyses. When inferential statistics were
performed, a P value of <.05 was considered statistically signiﬁcant. The P
values of all tests are reported without any correction for the multiplicity
of tests performed.
Safety assessment data of adverse events other than death or progression were not collected for this observational study.

RESULTS
Patient Disposition and Baseline Disease Characteristics
The disposition of patients with NHL and MM included
in the LTF study is described in Figure 1 and Figure 2, respectively. Patients from Studies 3101 and 3102 were included
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in the LTF study if they enrolled for the study, or for some
analyses (OS and PFS), data were included from patients who
had died before study initiation.
Of the original 289 patients with NHL from the Study 3101,
167 (58%) were enrolled in the LTF study. Of these 167 patients, 44 (26%) had received placebo and 123 (74%) had
received plerixafor either initially or following rescue. Of the
122 patients (42%) who did not enter the LTF study, 64 (26
in the placebo group, 38 in the plerixafor group), had died
before initiation of the LTF study, 31 (22 in the plerixafor
group) had been lost to follow-up, 21 (14 in the plerixafor
group) refused to participate, and 6 (4 in the plerixafor group)
from sites that declined to participate in the study.
Of the 294 patients with MM in Study 3102, 163 (55%) enrolled in the LTF study. Of these 163 patients, 72 received
placebo and 91 received plerixafor either as allocated treatment (n = 85) or as a rescue (n = 6). The remaining 131
patients (45%) who did not enroll in the LTF study comprised 40 who had died during and after Study 3102, 45 who
were lost to follow-up during or after Study 3102, 27 from
sites that declined to participate in the study, and 19 who
refused to participate.
Demographic data and baseline disease characteristics for
patients with NHL and MM who enrolled in the LTF study,
stratiﬁed by treatment group, are summarized in Tables 1 and
2, respectively. Demographic data and baseline data for patients with NHL and MM who enrolled in the original Studies
3101 and 3102 are summarized in Supplementary Table S1
and Supplementary Table S2, respectively.
The majority of patients who enrolled in the LTF study
were male (NHL, 68%; MM, 72%). The mean patient age was
57.4 years (standard deviation [SD], 9.9 years) in the NHL
patient population and 59.4 years (SD, 8.6 years) in the MM
group. Demographics were similar when stratiﬁed by treatment group and rescue for both the NHL and MM groups. The
most common baseline disease characteristics in the NHL population were Stage III disease (32%) and Stage IV disease (30%)
in the placebo group, and Stage IV disease (44%) in the
plerixafor group. The most common remission status at baseline was ﬁrst complete remission for both placebo-treated
(43%) and plerixafor-treated (31%) patients. The majority of
patients with MM who enrolled in the LTF study had Stage
III disease in both the plerixafor (55%) and placebo (56%)
groups, and most had a remission status of ﬁrst partial remission at baseline (82%).
Overall Survival
All 289 patients with NHL from Study 3101 and 294 patients with MM from Study 3102 contributed to the OS and
PFS analyses. Patients who did not enroll in the LTF study were
censored on either the date of their LTF study registration form
or by their last reported follow-up date within the Study 3101
or 3102 study periods.
Based on KM analysis, median OS was not achieved within
5 years of follow-up for either the placebo group or the
plerixafor group (Figure 3A). In the NHL population, 93 of the
289 patients (32%) died, including 32 of 88 (36%) in the
placebo group and 61 of 201 (30%) in the plerixafor group.
There was no statistically signiﬁcant difference in OS over 5
years between the placebo-treated and plerixafor-treated patients (log-rank test, P = .273; Wilcoxon test, P = .308). Findings
were similar for rescue and nonrescue patients (data not presented). The estimated 12, 24, 36, 48, and 60 month OS
probabilities for the placebo and plerixafor group are shown
in Table 3.
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Figure 1. Disposition of patients with NHL included in the 3101 LTF study.

In the MM population, 76 of 294 (26%) patients died, 35
of 142 (25%) patients in the placebo group and 41 of 152 (27%)
patients in the plerixafor group. Median OS was not reached
for either the placebo or plerixafor groups within 5 years of
follow-up (Figure 3B) and there was no statistically signiﬁcant difference in OS over 5 years between the placebotreated and plerixafor-treated patients (log-rank test, P = .936;
Wilcoxon test, P = .970). The estimated 12, 24, 36, 48, and
60 month OS probabilities for each treatment group are listed
in Table 3.
Progression Free Survival
Overall, 129 of 289 patients (45%) with NHL reported a
PFS event, including 43 of 88 (49%) in the placebo group and
86 of 201 (43%) in the plerixafor group. Median PFS was
reached in the placebo group at 39 months, but was not
reached in the plerixafor group within 5 years of follow-up.
However, the assessment of PFS over 5 years (Figure 4A)
showed no signiﬁcant difference between treatment groups

(log-rank test, P = .343; Wilcoxon test, P = .396). The estimated 12, 24, 36, 48, and 60 month PFS probabilities for the
placebo and plerixafor groups are summarized in Table 3.
One case of acute myeloid leukemia (AML) was observed in
an NHL patient who had received plerixafor plus G-CSF but
was considered by the treating physician to be unrelated to
plerixafor.
In the MM patient population, 172 of 294 patients (59%)
reported a PFS event, 70 of 142 patients (49%) in the placebo
group and 102 of 152 patients (67%) in the plerixafor group.
Median PFS was reached at 34 months for the placebo group
and at 26 months for the plerixafor group. A trend toward a
shorter PFS for patients treated with plerixafor than for those
receiving placebo (Figure 4B) was observed (log-rank test,
P = .061; Wilcoxon test, P = .138). Table 3 shows the estimated 12, 24, 36, 48, and 60 month PFS probabilities for each
treatment group. There were no cases of secondary MDS or
AML among patients with MM who had received plerixafor
plus G-CSF.
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Figure 2. Disposition of patients with MM included in the 3102 LTF study.

Composite Endpoint Analysis
During the period covering the end of recruitment to the
phase III studies and the observational phase data analysis,
several large studies were conducted to evaluate the possible beneﬁt of adding some form of maintenance or adjuvant
therapy post transplantation to attempt to improve the overall
outcome for patients with MM. To evaluate this effect on Study
3101, Study 3102, and the LTF study, a composite tripleendpoint analysis was undertaken (Supplementary Figures S1
and S2).
Overall, 166 of the 289 patients (57%) with NHL had a
triple-endpoint event, including 53 of 88 (60%) in the placebo
group and 113 of 201 (56%) in the plerixafor group. The
median triple endpoint was reached at 28 months in the
placebo group and at 24 months in the plerixafor group. No
signiﬁcant difference between placebo and plerixafor was
noted (log-rank test, P = .702; Wilcoxon test, P = .836). Table 3
summarizes the estimated 12, 24, 36, 48, and 60 month

triple-endpoint survival probabilities for the plerixafor and
placebo treatment groups.
In the MM patient population, 207 of 294 patients (70%)
had a triple-endpoint event, including 91 of 142 (64%) in the
placebo group and 116 of 152 (76%) in the plerixafor group.
Based on KM analysis, the median triple endpoint was reached
at 20 months for both treatment groups. There was no signiﬁcant difference between placebo and plerixafor for the
triple endpoint (log-rank test, P = .752, Wilcoxon test, P = .944).
The estimated 12, 24, 36, 48, and 60 month triple-endpoint
survival probabilities for both treatment groups are presented in Table 3.
DISCUSSION
This is the ﬁrst long-term observational study to assess
OS and PFS in patients with NHL and MM for a period of 5
years following the ﬁrst dose of study treatment (plerixafor
or placebo) in Studies 3101 and 3102. The results from this
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Table 1
Demographic Data and Baseline Characteristics of Patients with NHL Enrolled in the LTF Study
Variable/Statistic

Sex, n (%)
Male
Female
Ethnic origin, n (%)
Caucasian
African-American
Asian
Hispanic/Latino
Other
Age, yr
Mean (SD)
Median
Range
Weight, kg
Mean (SD)
Median
Range
Auto-HSCT following
treatment and apheresis,
n (%)
Disease stage at baseline,
n (%)†
I
II
III
IV
Missing
Remission status at
baseline, n (%)†
First/second CR
Relapse/second PR
Missing

Plerixafor
Group
(n = 123)*

Total
(n = 167)

29 (66)
15 (34)

85 (69)
38 (31)

114 (68)
53 (32)

43 (98)
0
1 (2)
0
0

118 (96)
1 (1)
1 (1)
3 (2)
0

161 (96)
1 (1)
2 (1)
3 (2)
0

58.4 (10.26)
58.5
27-74

57.1 (9.83)
59.0
29-75

57.4 (9.93)
59.0
27-75

87.5 (21.95)
87.8
56.5-178.0
42 (95)

87.3 (18.82)
85.6
48.6-159.6
121 (98)

87.4 (19.63)
86.3
48.6-178.0
163 (98)

Placebo
Group
(n = 44)

1 (2)
8 (18)
14 (32)
13 (30)
8 (18)

6 (5)
12 (10)
28 (23)
54 (44)
23 (19)

7 (4)
20 (12)
42 (25)
67 (40)
31 (19)

25 (57)
17 (38)
2 (5)

70 (57)
53 (43)
0

95 (57)
70 (42)
2 (1)

Table 2
Demographic Data and Baseline Characteristics of Patients with MM Enrolled in the LTF Study
Variable/Statistics

Sex, n (%)
Male
Female
Ethnic origin, n (%)
Caucasian
African-American
Asian
Hispanic/Latino
Other
Age, yr
Mean (SD)
Median
Range
Weight, kg
Mean (SD)
Median
Range
Auto-HSCT following
treatment and apheresis,
n (%)
Disease stage at baseline,
n (%)†
I
II
III
IV
Missing
Remission status at
baseline, n (%)†
First/second CR
Relapse/second PR
Missing

Plerixafor
Group
(n = 91)*

Total
(n = 163)

53 (74)
19 (26)

64 (70)
27 (30)

117 (72)
46 (28)

60 (83)
6 (8)
1 (1)
2 (3)
3 (4)

73 (80)
11 (12)
1 (1)
5 (5)
1 (1)

133 (82)
17 (10)
2 (1)
7 (4)
4 (2)

59.3 (9.06)
62.0
28-74

59.6 (8.18)
60.0
37-76

59.4 (8.56)
61.0
28-76

87.3 (18.51)
85.1
53.1-130.6
72 (100)

84.4 (18.48)
84.5
48.1-135.5
91 (100)

85.7 (18.49)
84.8
48.1-135.5
163 (100)

Placebo
Group
(n = 72)

8 (11)
18 (25)
40 (56)
0
6 (8)

15 (16)
16 (18)
50 (55)
0
10 (11)

23 (14)
34 (21)
90 (55)
0
16 (10)

11 (15)
61 (85)
0

8 (9)
83 (91)
0

19 (12)
144 (88)
0

SD indicates standard deviation; CR, complete remission; PR, partial remission.
* The plerixafor group includes 1 patient who was initially randomized
to placebo and subsequently underwent rescue with plerixafor.
† Baseline represents the point immediately before study drug
administration.

* The plerixafor group includes 1 patient who was initially randomized
to placebo and subsequently underwent rescue with plerixafor.
†
Baseline represents the point immediately before study drug was
administered.

LTF study suggest that the addition of plerixafor to G-CSF did
not have a detrimental effect on long-term survival.
The main limitation of this study is its observational nature.
In addition, only 58% of patients with NHL and 55% of patients with MM enrolled for the LTF study. However, because
data from patients who had previously died were included
in the analysis, 80% of the patients with NHL and 69% of those
with MM contributed to the OS and PFS data. The ﬁnding of
PFS data trending in opposite directions for patients with NHL
and those with MM was diﬃcult to interpret. The progression analyses contained limitations associated with data
collection and reporting during the study period, determination of true progression and the progression timeline
diﬃcult to ascertain. There was also an imbalance in patients who achieved complete remission following ablative
therapy in Studies 3101 and 3102. Progression data also may
have been confounded by inconsistent reporting of additional treatments used for maintenance or disease recurrence to
improve progression-free intervals [45,46]. Nonetheless, ﬁndings from the composite triple- endpoint analysis, which took
into account any reported potential maintenance medication, showed no statistically signiﬁcant difference in the
incidence of triple- endpoint events between the plerixafor
and placebo groups. A further limitation of the study is that
the sample size provided limited power and could detect only
a relatively large difference between the 2 groups.

Evaluating differences in OS and PFS between treatment
groups in the present investigation also served as a surrogate for the risk of potential detrimental outcome of the
mobilization of malignant cells from the bone marrow during
hematopoietic stem cell mobilization for auto-HCST. Our
ﬁnding of no statistically signiﬁcant difference in OS or PFS
following treatment with plerixafor plus G-CSF versus placebo
and G-CSF would seem to suggest that plerixafor does not
exert long-term deleterious effects as a result of tumor cell
mobilization. This observation is consistent with ﬁndings from
previous investigations demonstrating that plerixafor does
not contribute to tumor cell mobilization any more than G-CSF
alone does. A registry study is also underway in collaboration with the European Group for Blood and Marrow
Transplant to compare the outcomes of patients undergoing transplantation with plerixafor-mobilized and nonplerixafor-mobilized hematopoietic stem cells.
Other studies examining the effect of stem cell mobilization agents for auto-HSCT on long-term disease outcomes in
patients with NHL and patients with MM are limited, and the
paucity of long-term follow-up studies addressing OS and PFS
in patients with NHL and MM following stem cell mobilization and auto-HSCT highlights the importance of the present
study. Although the scarcity of published data restricts direct
comparison of this study with others, a retrospective analysis that evaluated long-term outcomes of plerixafor plus
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Figure 3. Overall survival in patients with NHL (A) and MM (B) stratiﬁed by treatment group.

G-CSF and G-CSF alone in patients with MM and lymphoma
(NHL and Hodgkin lymphoma), found a median PFS in the
plerixafor plus G-CSF group of 22.5 months in patients with
MM, comparable to our present ﬁnding, and a median OS of

Table 3
KM OS, PFS, and Triple-Endpoint Survival Probabilities at 12, 24, 36, 48, and
60 Months
Parameter

NHL Patients
Placebo

MM Patients
Plerixafor

Placebo

KM OS probability, % (95% CI)
12 mo
85 (76-91)
87 (81-91)
96 (91-98)
24 mo
71 (59-80)
78 (71-83)
87 (79-92)
36 mo
61 (49-72)
72 (65-78)
77 (67-84)
48 mo
60 (48-70)
68 (60-74)
67 (57-76)
60 mo
56 (44-67)
64 (56-71)
64 (53-73)
KM PFS probability, % (95% CI)
12 mo
72 (62-81)
75 (68-80)
88 (81-92)
24 mo
66 (55-76)
66 (58-72)
63 (53-72)
36 mo
54 (42-65)
58 (50-65)
46 (35-55)
48 mo
48 (36-59)
54 (46-61)
34 (25-44)
60 mo
43 (31-54)
50 (42-58)
30 (21-40)
Triple-endpoint survival probability, % (95% CI)
12 mo
60 (49-69)
60 (52-66)
64 (56-72)
24 mo
55 (44-65)
49 (42-56)
43 (34-53)
36 mo
44 (33-55)
41 (34-49)
28 (19-38)
48 mo
38 (27-49)
40 (32-47)
19 (11-28)
60 mo
31 (20-42)
37 (29-44)
14 (7-23)

Plerixafor
95 (90-98)
87 (79-92)
77 (69-84)
70 (60-77)
64 (54-72)
83 (76-88)
57 (48-65)
38 (30-47)
24 (17-32)
17 (10-24)
64 (56-71)
42 (33-50)
27 (20-35)
16 (10-24)
11 (6-17)

40 months. However, the authors did not compare OS and
PFS between plerixafor plus G-CSF and G-CSF alone because
of the study’s retrospective nature and small sample size [15].
Within the wider context of other studies examining longterm outcomes following auto-HSCT, our ﬁndings, which show
that more than one-half of patients remained alive 5 years
after transplantation, echo those of several previous
studies―that is, auto-HSCT is associated with extended OS
[5,6,46].
In conclusion, although this follow-up study is limited by
its observational design, our results suggest that the use of
plerixafor plus G-CSF does not have a negative outcome on
OS and PFS at 5 years in these patients with NHL or MM.
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